Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S Statistics
Share Statistics
Ascendis Pharma A/S has 59.84M shares outstanding. The number of shares has increased by 5.56% in one year.
| Shares Outstanding | 59.84M |
| Shares Change (YoY) | 5.56% |
| Shares Change (QoQ) | 4.2% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 59.14M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 3.41M, so 5.7% of the outstanding shares have been sold short.
| Short Interest | 3.41M |
| Short % of Shares Out | 5.7% |
| Short % of Float | 5.75% |
| Short Ratio (days to cover) | 8.5 |
Valuation Ratios
The PE ratio is -20.16 and the forward PE ratio is -35. Ascendis Pharma A/S's PEG ratio is 0.88.
| PE Ratio | -20.16 |
| Forward PE | -35 |
| PS Ratio | 20.97 |
| Forward PS | 3.1 |
| PB Ratio | -72.12 |
| P/FCF Ratio | -24.78 |
| PEG Ratio | 0.88 |
Enterprise Valuation
Ascendis Pharma A/S has an Enterprise Value (EV) of 6.67B.
| EV / Earnings | -17.63 |
| EV / Sales | 18.33 |
| EV / EBITDA | -22.98 |
| EV / EBIT | -23.91 |
| EV / FCF | -21.67 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of -8.1.
| Current Ratio | 1.17 |
| Quick Ratio | 0.84 |
| Debt / Equity | -8.1 |
| Total Debt / Capitalization | 114.08 |
| Cash Flow / Debt | -0.36 |
| Interest Coverage | -4.26 |
Financial Efficiency
Return on equity (ROE) is 3.58% and return on capital (ROIC) is -37.61%.
| Return on Equity (ROE) | 3.58% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -37.61% |
| Revenue Per Employee | 357.56K |
| Profits Per Employee | -371.76K |
| Employee Count | 1.02K |
| Asset Turnover | 0.31 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | 4.84M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -1.49% in the last 52 weeks. The beta is 0.64, so Ascendis Pharma A/S's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -1.49% |
| 50-Day Moving Average | 133.16 |
| 200-Day Moving Average | 132.59 |
| Relative Strength Index (RSI) | 69.67 |
| Average Volume (20 Days) | 457.98K |
Income Statement
In the last 12 months, Ascendis Pharma A/S had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.59.
| Revenue | 363.64M |
| Gross Profit | 319.38M |
| Operating Income | -278.76M |
| Net Income | -378.08M |
| EBITDA | -290.02M |
| EBIT | -278.76M |
| Earnings Per Share (EPS) | -6.59 |
Balance Sheet
The company has 559.54M in cash and 856.62M in debt, giving a net cash position of -297.07M.
| Cash & Cash Equivalents | 559.54M |
| Total Debt | 856.62M |
| Net Cash | -297.07M |
| Retained Earnings | 0 |
| Total Assets | 1.18B |
| Working Capital | 153.00M |
Cash Flow
In the last 12 months, operating cash flow was -306.20M and capital expenditures -1.43M, giving a free cash flow of -307.62M.
| Operating Cash Flow | -306.20M |
| Capital Expenditures | -1.43M |
| Free Cash Flow | -307.62M |
| FCF Per Share | -5.36 |
Margins
Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.
| Gross Margin | 87.83% |
| Operating Margin | -76.66% |
| Pretax Margin | -102.64% |
| Profit Margin | -103.97% |
| EBITDA Margin | -79.76% |
| EBIT Margin | -76.66% |
| FCF Margin | -84.6% |
Dividends & Yields
ASND does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.26% |
| FCF Yield | -3.32% |
Analyst Forecast
The average price target for ASND is $186, which is 20.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $186 |
| Price Target Difference | 20.2% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 4 |
| Piotroski F-Score | 4 |